Dutch Bros Stock Is Sinking After Hours: What’s Going On?

Dutch Bros Inc (NYSE: BROS) shares are trading lower in Wednesday's after-hours session after the company reported mixed 

Dutch Bros Inc (NYSE:BROS) shares are trading lower in Wednesday’s after-hours session after the company reported mixed fourth-quarter results.

What Happened: Dutch Bros said fourth-quarter revenues increased 44.1% year-over-year to $201.8 million, which beat consensus estimates of $195.76 million. The fast-growing Starbucks Corp (NASDAQ: SBUX) competitor reported quarterly earnings of just 3 cents per share, which missed estimates of 7 cents per share.

Dutch Bros opened 30 new stores during the fourth quarter bringing total new store openings up to 133 for the year. 

“For the third consecutive year, we have exceeded our new shop development targets, doubling our shop count since March 2019, despite unprecedented disruption to communities and the economy,” said Joth Ricci, CEO of Dutch Bros.

“This year, we are targeting 150 new systemwide shops, which will enable us to achieve our five-year goal of 800 systemwide shops by year-end. Additionally, we expect to be within striking distance of $1 billion in revenue in 2023 and 1,000 systemwide shops by the first half of 2025,” he added.

Dutch Bros expects full-year 2023 revenue to be between $950 million and $1 billion versus estimates of $980.63 million. Full-year adjusted EBITDA is expected to be approximately $125 million.

See Also: After-Hours Alert: Why Teladoc Stock Is Diving

BROS Price Action: Dutch Bros shares are down 7.56% after hours at $35.10 at the time of publication, according to Benzinga Pro.

Photo: courtesy of Dutch Bros.

Total
0
Shares
Related Posts
Read More

Cellectis Announces Pricing Of Follow-On $20.2M Public Offering Of 8.8M American Depositary Shares At A Price Of $2.50/ADS; Plans To Use ~$17M Of Proceeds To Fund The Continued Clinical Development Of UCART 123, UCART22, UCART20x22, And UCARTCS1

Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces

CLLS

Read More

Recap: Delek US Hldgs Q3 Earnings

Delek US Hldgs (NYSE:DK) reported its Q3 earnings results on Monday, November 7, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Delek US Hldgs missed estimated earnings by 75.0%, reporting an EPS of $0.02 versus an estimate of $0.08.

DK